Cheryl Guttman Krader
Published: Wednesday, July 5, 2017
In patients with retinal vein occlusion (RVO), the presence or absence of central or peripheral ischemia at baseline may influence visual function at baseline and the course of best corrected visual acuity (BCVA) over time, suggest recent clinical trial findings.
The number of anti-VEGF injections or corticosteroid implants used for the treatment of branch RVO (BRVO) or central RVO (CRVO), however, may not be affected by these baseline ischaemia characteristics, according to Amelie Pielen MD.
“These initial investigations of the influence of baseline ischaemia were conducted as a secondary analysis using descriptive techniques. Now we are analysing the data for statistical significance,” said Dr Pielen, Department of Ophthalmology, Hannover Medical School, Hannover, Germany.
The COMRADE-B and COMRADE-C studies randomised 487 patients with visual impairment from macular oedema secondary to BRVO or CRVO to ranibizumab 0.5mg (Lucentis) or the dexamethasone 0.7mg implant (Ozurdex). Ranibizumab was given as a mandatory three monthly injections and then as needed. At 6 months, 175 patients enrolled in the COMRADE-Extension study comparing as needed ranibizumab and as needed dexamethasone implant treatment through month 12.
At baseline, investigators evaluated fluorescein angiography images for the presence of an enlarged central avascular area and for the presence and extent of peripheral retinal non-perfusion (PNP). Overall among the BRVO patients, about 25% had an enlarged central avascular area and about 35% had PNP. In the CRVO study, 10% of patients in the ranibizumab group and 22.7% of dexamethasone patients had an enlarged central avascular area while about 20% of patients in both treatment groups had PNP present.
Other comparisons between treatment groups in the two COMRADE studies showed them to be similar in their demographic characteristics except mean BCVA was lower in patients with an enlarged central avascular area versus in those without in both the BRVO (56.8 vs. 58.3 letters) and CRVO (68.9 vs. 81.8 letters) study groups. The same pattern was seen comparing eyes with and without PNP in both COMRADE studies.
Among ranibizumab-treated patients, BCVA gains from baseline to month 15 were similarly high independent of baseline central avascular area or PNP status (minimum mean gain 14.7 letters). Among CRVO patients, however, those with an enlarged central avascular area randomised to the corticosteroid implant lost vision over time (-6.4 letters).
In both the CRVO and BRVO cohorts and for both treatment groups, the mean number of treatments received was similar regardless of baseline ischaemic status. Across the subgroups with and without an enlarged central avascular area and among those with and without PNP, the mean number of ranibizumab injections was in the range of 7 to 8 while the average number of dexamethasone implants was about 1 to 1.5.
ENDS
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
Read more...
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Read more...
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Read more...
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Read more...
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Read more...
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Read more...
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Read more...
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Read more...
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
Read more...
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Read more...